Risk Factors for Cardiac and Non-cardiac Causes of Death in Males with Duchenne Muscular Dystrophy.
Duchenne muscular dystrophy
Dystrophic cardiomyopathy
Heart failure
Sudden cardiac death
Journal
Pediatric cardiology
ISSN: 1432-1971
Titre abrégé: Pediatr Cardiol
Pays: United States
ID NLM: 8003849
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
09
10
2019
accepted:
22
01
2020
pubmed:
6
2
2020
medline:
5
6
2020
entrez:
5
2
2020
Statut:
ppublish
Résumé
As survival and neuromuscular function in Duchenne muscular dystrophy (DMD) have improved with glucocorticoid (GC) therapy and ventilatory support, cardiac deaths are increasing. Little is known about risk factors for cardiac and non-cardiac causes of death in DMD. A multi-center retrospective cohort study of 408 males with DMD, followed from January 1, 2005 to December 31, 2015, was conducted to identify risk factors for death. Those dying of cardiac causes were compared to those dying of non-cardiac causes and to those alive at study end. There were 29 (7.1%) deaths at a median age of 19.5 (IQR: 16.9-24.6) years; 8 (27.6%) cardiac, and 21 non-cardiac. Those living were younger [14.9 (IQR: 11.0-19.1) years] than those dying of cardiac [18 (IQR 15.5-24) years, p = 0.03] and non-cardiac [19 (IQR: 16.5-23) years, p = 0.002] causes. GC use was lower for those dying of cardiac causes compared to those living [2/8 (25%) vs. 304/378 (80.4%), p = 0.001]. Last ejection fraction prior to death/study end was lower for those dying of cardiac causes compared to those living (37.5% ± 12.8 vs. 54.5% ± 10.8, p = 0.01) but not compared to those dying of non-cardiac causes (37.5% ± 12.8 vs. 41.2% ± 19.3, p = 0.58). In a large DMD cohort, approximately 30% of deaths were cardiac. Lack of GC use was associated with cardiac causes of death, while systolic dysfunction was associated with death from any cause. Further work is needed to ensure guideline adherence and to define optimal management of systolic dysfunction in males with DMD with hopes of extending survival.
Identifiants
pubmed: 32016582
doi: 10.1007/s00246-020-02309-y
pii: 10.1007/s00246-020-02309-y
pmc: PMC7328368
mid: NIHMS1602690
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
764-771Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK114477
Pays : United States
Références
Lancet Neurol. 2018 Mar;17(3):251-267
pubmed: 29395989
Neuromuscul Disord. 2014 Jun;24(6):482-91
pubmed: 24780148
Lancet Neurol. 2018 Apr;17(4):347-361
pubmed: 29395990
Muscle Nerve. 2018 Aug;58(2):219-223
pubmed: 29543994
Heart Fail Rev. 2014 Aug;19(4):453-70
pubmed: 25062653
Neuromuscul Disord. 2008 May;18(5):365-70
pubmed: 18436445
Acta Myol. 2012 Oct;31(2):117-20
pubmed: 23097602
J Am Heart Assoc. 2017 Oct 17;6(10):
pubmed: 29042427
Neuromuscul Disord. 2011 Jan;21(1):47-51
pubmed: 21144751
J Pediatr. 2013 Oct;163(4):1080-4.e1
pubmed: 23866715
Neuromuscul Disord. 2017 Aug;27(8):730-737
pubmed: 28645460
Am Heart J. 1994 Mar;127(3):618-23
pubmed: 8122611
J Am Coll Cardiol. 2013 Mar 5;61(9):948-54
pubmed: 23352781
J Am Heart Assoc. 2015 Dec 31;5(1):
pubmed: 26722125
Ann Phys Rehabil Med. 2013 Sep;56(6):443-54
pubmed: 23876223
J Child Neurol. 2015 Sep;30(10):1275-80
pubmed: 25414237
Neuromuscul Disord. 2006 Apr;16(4):249-55
pubmed: 16545568
Respir Care. 2011 Jun;56(6):744-50
pubmed: 21333078
J Child Neurol. 2010 Sep;25(9):1116-29
pubmed: 20581335
Int J Cardiol. 1990 Mar;26(3):271-7
pubmed: 2312196
Neuromuscul Disord. 2017 Feb;27(2):107-114
pubmed: 28003112
Pediatrics. 2015 Mar;135(3):513-21
pubmed: 25687144
Acta Myol. 2012 Oct;31(2):121-5
pubmed: 23097603
Pediatr Neurol. 2008 Mar;38(3):200-6
pubmed: 18279756
Neuromuscul Disord. 1993 May;3(3):201-6
pubmed: 7691292